Adherex Technologies Inc.
Description Adherex Technologies Inc., together with its subsidiary, Adherex, Inc., operates as a development stage biopharmaceutical company with a portfolio of product candidates under development for use in the treatment of cancer. It focuses on the development of Eniluracil, which is in phase II clinical trials to treat of cancer. Eniluracil is an irreversible inhibitor of dihydropyrimidine dehydrogenase, the enzyme primarily responsible for the rapid breakdown of 5-fluorouracil in the body. The company is also developing Sodium Thiosulfate, a protectant against the hearing loss often caused by platinum-based anti-cancer agents in children, which is in phase III clinical trials. Adherex Technologies Inc. was founded in 1996 and is based in Research Triangle Park, North Carolina. To view the detailed information, you need to SUBSCRIBE with us. |
 |